Benzinga | Nov 5, 2020 05:15PM EST

Sarepta Therapeutics Q3 EPS $(1.42) Beats $(1.71) Estimate, Sales $143.92M Beat $137.43M Estimate

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(1.42) per share which beat the analyst consensus estimate of $(1.71) by 16.96 percent. This is a 24.56 percent decrease over losses of $(1.14) per share from the same period last year. The company reported quarterly sales of $143.92 million which beat the analyst consensus estimate of $137.43 million by 4.73 percent. This is a 45.32 percent increase over sales of $99.04 million the same period last year.